A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study With a Food-Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects and Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs AMG 581 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Amgen
- 22 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Oct 2015 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health - NCT02567370).
- 24 Apr 2015 New trial record